Maria Themeli,Michel Sadelain,Christopher C. Kloss
申请号：
US16443219
公开号：
US20190375850A1
申请日:
2019.06.17
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention relates to the field of adoptive immunotherapy. The invention provides methods for generating phenotypically defined, functional, and/or expandable T cells from pluripotent stem cells engineered through safe genetic modifications. The engineered cells may provide one or more of: 1) targeting a specific predetermined antigen expressed on the cell surface of a target cell in an HLA independent manner, 2) enhanced survival and functional potential 3) “off-the-shelf” T cells for administration to multiple recipients, eventually across immunogenic barriers, and/or 4) cytotoxic potential and anti-tumor activity.
